Fig.2 Pleiotropic effects of GLP1-RA leading to improvement MASLD/MASH [2] GLP-1RA in MASH Treatment: Clinical Progress Several GLP-1RAs and related agents are currently in various phases of clinical development for MASH treatment [4]
Acebes-Huerta A, Arias-Fernndez T, Bernardo , et al
Its role is to: Enhance insulin secretion when blood sugar rises Reduce glucagon secretion , lowering blood glucose production Slow stomach emptying , which promotes satiety Reduce appetite , leading to weight loss Since natural GLP-1 breaks down quickly, drug companies created synthetic GLP-1 receptor agonists (like semaglutide in Ozempic/Wegovy) that stay active longer
Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
